Linezolid-related adverse effects in the treatment of rifampicin resistant tuberculosis: a retrospective study

References

• Byrne AL, Marais BJ, Mitnick CD, et al. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis. 2015;32:138–146.
   PubMed Web of Science ®Google Scholar
• World health organization. Global tuberculosis report 2018. Geneva, Switzerland: World Health Organization; 2018.
   Google Scholar
• Kendall EA, Sahu S, Pai M, et al. What will it take to eliminate drug-resistant tuberculosis? Int J Tuberc Lung Dis. 2019;23(5):535–546.
   PubMed Web of Science ®Google Scholar
• Sharma D, Deo N, Bisht D. Proteomics and bioinformatics: a modern way to elucidate the resistome in Mycobacterium tuberculosis. J Proteomics Bioinf. 2017;10(6):1000e33.
   PubMedGoogle Scholar
• Lange C, Dheda K, Chesov D, et al. Management of drug-resistant tuberculosis. Lancet. 2019;394(10202):953–966.
   PubMed Web of Science ®Google Scholar
• Palomino JC, Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel). 2014;3(3):317–340.
   PubMedGoogle Scholar
• Isakova J, Sovkhozova N, Vinnikov D, et al. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in kyrgyz republic. BMC Microbiol. 2018;18(1):22.
   PubMedGoogle Scholar
• Osei Sekyere J, Maningi NE, Fourie PB. Mycobacterium tuberculosis, antimicrobials, immunity, and lung-gut microbiota crosstalk: current updates and emerging advances. Ann NY Acad Sci. 2020;1467(1):21–47.
   PubMed Web of Science ®Google Scholar
• Kurz SG, Furin JJ, Bark CM. Drug-resistant tuberculosis: challenges and progress. Infect Dis Clin North Am. 2016;30(2):509–522.
   PubMed Web of Science ®Google Scholar
• Gualano G, Capone S, Matteelli A, et al. New antituberculosis drugs: from clinical trial to programmatic use. Infect Dis Rep. 2016;8(2):6569.
   PubMedGoogle Scholar
• Mikiashvili L, Kipiani M, Schechter MC, et al. Linezolid use for drug-resistant tuberculosis in Georgia: a retrospective cohort study. Int J Tuberc Lung Dis. 2020;24(4):436–443.
   PubMed Web of Science ®Google Scholar
• Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and Meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7(4):603–615.
   PubMed Web of Science ®Google Scholar
• Ager S, Gould K. Clinical update on linezolid in the treatment of gram-positive bacterial infections. Infect Drug Resist. 2012;5:87–102.
   PubMedGoogle Scholar
• Polikanov YS, Aleksashin NA, Beckert B, et al. The mechanisms of action of Ribosome-Targeting peptide antibiotics. Front Mol Biosci. 2018;5:48.
   PubMed Web of Science ®Google Scholar
• Hoagland DT, Liu J, Lee RB, et al. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev. 2016;102:55–72.
   PubMed Web of Science ®Google Scholar
• de Miranda Silva C, Hajihosseini A, Myrick J, et al. Effect of linezolid plus bedaquiline against Mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay. Antimicrob Agents Chemother. 2018;62(8):e00856–18.
   PubMed Web of Science ®Google Scholar
• Koch A, Cox H, Mizrahi V. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Curr Opin Pharmacol. 2018;42:7–15.
   PubMed Web of Science ®Google Scholar
• Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38(3):516–528.
   PubMed Web of Science ®Google Scholar
• Singh B, Cocker D, Ryan H, et al. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;3(3):CD012836.
   PubMedGoogle Scholar
• Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508–1518.
   PubMed Web of Science ®Google Scholar
• Qiao J, Cheng C, Feng J, et al. Analysis of efficacy and safety of linezolid-based chemotherapeutic regimens for postoperative multidrug-resistant spinal tuberculosis patients. Int J Infect Dis. 2022;118:264–269.
   PubMed Web of Science ®Google Scholar
• Park M, Satta G, Kon OM. Kon OM an update on multidrug-resistant tuberculosis. Clin Med (Lond). 2019;19(2):135–139.
   PubMed Web of Science ®Google Scholar
• Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and Meta-analysis. Ann Clin Microbiol Antimicrob. 2016;15(1):41.
   PubMed Web of Science ®Google Scholar
• Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45(1):161–170.
   PubMed Web of Science ®Google Scholar
• Lee M, Cho SN, Barry CE, et al. Linezolid for XDR-TB–final study outcomes. N Engl J Med. 2015;373(3):290–291. 3rd
   PubMed Web of Science ®Google Scholar
• Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and Meta-analysis. Int J Tuberc Lung Dis. 2012;16(4):447–454.
   PubMed Web of Science ®Google Scholar
• Huang HR, Yu X, Jiang GL. Treatment outcomes of linezolid for multidrug-resistant tuberculosis: a systematic review and Meta-analysis. Chin J Antituberculosis. 2011;33(5):275.
   Google Scholar
• Koh WJ, Kang YR, Jeon K, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother. 2012;67(6):1503–1507.
   PubMed Web of Science ®Google Scholar
• Rao GG, Konicki R, Cattaneo D, et al. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2020;42(1):83–92.
   PubMed Web of Science ®Google Scholar